INDICATION

EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis.

Please see below for Important Safety Information for EPCLUSA.

FREQUENTLY ASKED QUESTIONS

ABOUT EPCLUSA

What is EPCLUSA (sofosbuvir/velpatasvir) used or indicated for?
Can EPCLUSA be used to treat hepatitis C in people who inject drugs?
Has EPCLUSA been studied in patients that have experienced challenges with treatment adherence?
Is there information about EPCLUSA and drug interactions with concomitant medications?
Has EPCLUSA been studied in patients receiving medication for opioid use disorder (MOUD)/opioid substitution therapy?
What other populations can EPCLUSA (sofosbuvir/velpatasvir) be used to treat?
How long does EPCLUSA (sofosbuvir/velpatasvir) need to be taken for?
Are there any food or meal requirements for adults taking EPCLUSA?
Regarding the Boxed Warning for patients with HBV coinfection, what are some considerations when treating with EPCLUSA?
Does EPCLUSA contain a protease inhibitor?
Is there any financial support available for patients starting EPCLUSA?
How does EPCLUSA (sofosbuvir/velpatasvir) work?
View Clinical Resources

ABOUT HEPATITIS C

What is the difference between acute hepatitis C and chronic hepatitis C?
What specific populations should be screened or tested for hepatitis C?
What are the steps for diagnosing and treating a patient with hepatitis C?